These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7831443)

  • 1. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.
    Hagan RM; Kilpatrick GJ; Tyers MB
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S68-75. PubMed ID: 7831443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin/dopamine interaction--focus on 5-HT2C receptor, a new target of psychotropic drugs.
    Di Giovanni G; Di Matteo V; Esposito E
    Indian J Exp Biol; 2002 Dec; 40(12):1344-52. PubMed ID: 12974395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.
    Engleman EA; Rodd ZA; Bell RL; Murphy JM
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):454-67. PubMed ID: 19128203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 5-HT3 receptors in drug dependence.
    Grant KA
    Drug Alcohol Depend; 1995 May; 38(2):155-71. PubMed ID: 7671767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ; Tyers MB
    Pharmacol Ther; 1990; 47(2):181-202. PubMed ID: 2203069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
    Ellenbroek BA; Prinssen EP
    Behav Pharmacol; 2015 Feb; 26(1-2):33-44. PubMed ID: 25356732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system.
    Kilpatrick GJ; Hagan RM; Gale JD
    Behav Brain Res; 1996; 73(1-2):11-3. PubMed ID: 8788470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding.
    Koulu M; Lappalainen J; Hietala J; Sjöholm B
    Psychopharmacology (Berl); 1990; 101(2):168-71. PubMed ID: 2140903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the A10 dopamine system: electrophysiological studies of the role of 5-HT3-like receptors.
    Wang RY; Ashby CR; Zhang JY
    Behav Brain Res; 1996; 73(1-2):7-10. PubMed ID: 8788469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties and functions of central 5-HT3 receptors.
    Costall B; Naylor RJ
    Therapie; 1991; 46(6):437-44. PubMed ID: 1840228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and psychiatric disorders. A key to new therapeutic approaches.
    Costall B; Naylor RJ
    Arzneimittelforschung; 1992 Feb; 42(2A):246-9. PubMed ID: 1586395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat.
    Hagan RM; Jones BJ; Jordan CC; Tyers MB
    Br J Pharmacol; 1990 Feb; 99(2):227-32. PubMed ID: 1691672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT(2C/2B) receptor antagonists: neurochemical and behavioural studies.
    Hutson PH; Barton CL; Jay M; Blurton P; Burkamp F; Clarkson R; Bristow LJ
    Neuropharmacology; 2000 Sep; 39(12):2318-28. PubMed ID: 10974315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioural pharmacology of 5-HT3 receptor ligands.
    Barnes JM; Barnes NM; Cooper SJ
    Neurosci Biobehav Rev; 1992; 16(1):107-13. PubMed ID: 1553101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astra Award Lecture. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Dec; 71(6):401-15. PubMed ID: 1362267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antipsychotic potential of subtype-selective 5-HT receptor ligands based on interactions with mesolimbic dopamine systems.
    Tricklebank MD
    Behav Brain Res; 1996; 73(1-2):15-7. PubMed ID: 8788471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction.
    Tricklebank MD
    Trends Pharmacol Sci; 1989 Apr; 10(4):127-9. PubMed ID: 2665244
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens.
    Chen JP; van Praag HM; Gardner EL
    Brain Res; 1991 Mar; 543(2):354-7. PubMed ID: 1711914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.